COMPOSITION WITH SUSTAINED RELEASE OF THIAZOLIDINE DIONE DERIVATIVE AND ITS USE FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS AND CONDITIONS ASSOCIATED WITH DIABETES MELLITUS

摘要

The invention relates to medicine and pharmaceutics and concerns sustained release pharmaceutical compositions. A sustained release pharmaceutical composition is in the unit dose and suitable for oraladministration. It comprises from 2 to 12 mg of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy] benzyl] thiazolidine-2,4-dione or pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable carrier. It provides concentration of the active agent in plasma on the level at least 50 ng/ml over a time period of up to 24 hours.